INTRODUCTION Autologous intraoperative blood salvage (IBS) is used routinely in many surgical specialties to minimize the effects of intraoperative bleeding, avoiding the risks of allogeneic red blood cell (RBC) transfusion. A recent cochrane review showed a 40% reduction in the requirements for allogeneic blood transfusion with cell salvage[1]. IBS has been generally used in liver transplantation (LT), although it is not usually recommended in patients with hepatocellular carcinoma (HCC) since there is a putative risk of reinfusion of
Leptospirosis has been rarely reported in solid organ transplant recipients. We report the first case to our knowledge of leptospirosis in a liver transplant recipient who developed jaundice and renal insufficiency. We describe his favorable clinical progression and discuss the possible mechanisms involved in the more benign disease course. We also review the previously published cases of leptospirosis in solid organ transplant recipients. Although this disease does not appear to present any particularities in this context, we highlight the importance
BACKGROUND: Late acute rejection (LAR) differs in its clinical and histological presentation and management from early acute rejection. This clinical entity is not completely understood; thus, we aimed to identify significant prognostic factors that can influence post-transplant survival in LAR patients. The purpose of this study was to evaluate the incidence and post-transplant survival of patients from a single center with a focus on late acute rejection. MATERIAL AND METHODS: From January 2002 to June 2013, all liver biopsies from patients
INTRODUÇÃO Na população geral, a incidência das variações anatômicas da artéria hepática variam de 20 a 50% em diferentes séries4,11,13,23. Desde o artigo original de Michels et al.20, vários estudos têm seguido o seu trabalho e desenvolvido sistemas de classificação para as variações anatômicas das artérias hepáticas1,10,12,13,17. Por conseguinte, a procura pelo diagnóstico destas variações e o desenvolvimento de técnicas de reconstrução vascular para otimizar a irrigação da árvore biliar e do enxerto
INTRODUCTION The classification of levels of evidence for Brazilian Society of Hepatology recommendations for the diagnosis, staging, and treatment of hepatocellular carcinoma is based on a modification of the GRADE approach, as follows: Grade of evidence (according to the GRADE SYSTEM REFERENCE). A – High quality – Future research is unlikely to change the presented proposition B – Moderate quality – Future research may have a significant impact on the presented proposition C – Low or very low quality – Future research is very
INTRODUCTION Acute liver failure is associated with a high mortality rate and the main purposes of treatment are to prevent cerebral edema and infections, which often are responsible for patient death1. The orthotopic liver transplantation is the gold standard treatment and improves the 1-year survival over than 60%1. Auxiliary liver transplantation (ALT) is an accepted modality for selected recipients with ALF5. Gubernatis et al.4 reported the first successful ALT for ALF in 19914. There are three described
INTRODUCTION Acute cellular rejection has been a common cause of graft loss and an indication for re-transplantation. Advances in immunosuppression have improved the outcome of transplantation 7 . However, late acute rejection appears to result in a different outcome with worse patient and graft survival after liver transplantation 7 9 . Late acute rejection has been variably defined as ocurring more than one, three, or six months after transplantation. Therefore, it differs from early acute cellular rejection, which occurs
BackgroundLiver transplantation has received increased attention in the medical field since the 1980s following the introduction of new immunosuppressants and improved surgical techniques. Currently, transplantation is the treatment of choice for patients with end-stage liver disease, and it has been expanded for other indications. Liver transplantation outcomes depend on donor factors, operating conditions, and the disease stage of the recipient. A retrospective cohort was studied to identify mortality and graft failure rates and their associated factors. All
Abstract Non-alcoholic fatty liver disease encompasses a spectrum of liver diseases, including simple steatosis, steatohepatitis, liver fibrosis and cirrhosis and hepatocellular carcinoma. Non-alcoholic fatty liver disease is currently the most dominant chronic liver disease in Western countries due to the fact that hepatic steatosis is associated with insulin resistance, type 2 diabetes mellitus, obesity, metabolic syndrome and drug-induced injury. A variety of chemicals, mainly drugs, and diets is known to cause hepatic steatosis in humans and rodents. Experimental non-alcoholic fatty liver
Mauris id enim id purus ornare tincidunt. Aenean vel consequat risus. Proin viverra nisi at nisl imperdiet auctor. Donec ornare, est sed tincidunt placerat, sem mi suscipit mi, at varius enim sem at sem. Fusce tempus ex nibh, eget vulputate ligula ornare eget. Nunc facilisis erat at ligula blandit tempor. Mauris iaculis magna ipsum, sit amet pretium risus dictum cursus. Morbi id massa sed risus eleifend rutrum. Mauris lorem diam, fermentum sed lorem ac, maximus efficitur sapien. Aenean condimentum ornare